Effect of five years of treatment with nipradilol eye drops in patients with normal tension glaucoma

Clinical Ophthalmology

Volumn 5, Issue 1, 2011, Pages 1211-1216

  Inoue, Kenji ^a   Noguchi, Kei ^a   Wakakura, Masato ^a   Tomita, Goji ^b  

^a Inoue Eye Hospital   (Japan)

^b TOHO UNIVERSITY   (Japan)

Author keywords

Event analysis; Heidelberg retina tomograph ii; Intraocular pressure; Nipradilol; Trend analysis

Indexed keywords

EYE DROPS; NIPRADILOL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; INTRAOCULAR PRESSURE; LOW TENSION GLAUCOMA; MALE; OPTIC DISK CUP DEPTH; OPTIC DISK CUP HEIGHT; PERIMETRY; PRESSURE MEASUREMENT; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL FIELD; VISUAL SYSTEM PARAMETERS;

EID: 81055140879     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/opth.s23233     Document Type: Article

References (20)

1. Collaborative Normal Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normaltension glaucoma and patients with therapeutically reduced intraocular pressure. Am J Ophthalmol. 1998;126:487-497.
2. Collaborative Normal Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126:498-505.
3. Noureddin BN, Poinoosawmy D, Fietzke FW, Hitchinqs RA. Regression analysis of visual field progression in low tension glaucoma. Br J Ophthalmol. 1991;75:493-495.
4. The Advanced Glaucoma Intervention Study Investigators. Advanced Glaucoma Intervention Study 2. Visual field test scoring and reliability. Ophthalmology. 1994;101:1445-1455.
5. McNaught AL, Crabb DP, Fitzke FW, Hitchinqs RA. Visual field progression: Comparison of Humphrey Statpac 2 and pointwise linear regression analysis. Graefes Arch Clin Exp Ophthalmol. 1996;234:411-418.
6. Flammer J, Drance SM, Auqustiny L, Funkhouser A. Quantification of glaucomatous visual field defects with automated perimetry. Invest Ophthalmol Vis Sci. 1985;26:176-181.
7. Tomita G, Araie M, Kitazawa Y, Tsukahara S. A three-year prospective, randomized and open comparison between latanoprost and timolol in Japanese normal-tension glaucoma patients. Eye. 2004;18:984-989.
8. Inoue K, Wakakura M, Inoue J, Tomita G. Effect of nipradilol instillation for three years in eyes with normal-tension glaucoma. Jpn J Clin Ophthalmol. 2008;62:323-327.
9. Kalaboukhova L, Fridhammar V, Lindblom B. Glaucoma follow-up by the Heidelberg retina tomograph - new graphical analysis of optic disc topography changes. Graefes Arch Clin Exp Ophthalmol. 2006;244:654-662.
10. Harju M, Saari J, Kurvinen L, Vesti E. Reversal of optic disc cupping in glaucoma. Br J Ophthalmol. 2008;92:901-905.
11. Uchida Y, Nakamura M, Shimizu S, Shirasawa Y, Fujii M. Vasoactive and beta-adrenoceptor blocking properties of 3, 4-dihydro-8- (2-hydroxy-3-isopropylamino) propoxy-3-nitroxy-2H-1-benzopyran (K-351), a new antihypertensive agent. Arch Int Pharmacodyn Ther. 1983;262:132-149.
12. Ohira A, Wada Y, Fujii M, et al. Effects of nipradilol (K-351) on alphaadrenoceptor mediated responses in various isolated tissues. Arch Int Pharmacodyn Ther. 1985;278:61-71.
13. Kanno M, Araie M, Tomita K, Sawanobori K. Effects of nipradilol, a?-blocking agent with?-blocking and nitroglycerin-like activities, on aqueous humor dynamics and fundus circulation. Invest Ophthalmol Vis Sci. 1998;39:736-743.
14. Kanno M, Araie M, Koibuchi H, Masuda K. Effects of topical nipradilol, a??blocking agent with??blocking and nitroglycerin-like activities, on intraocular pressure and aqueous dynamics in humans. Br J Ophthalmol. 2000;84:293-299.
15. Yukawa E, Taketani F, Matsuura T, et al. Ocular hypotensive effect of nipradilol ophthalmic solution for normal-tension glaucoma. Jpn J Clin Ophthalmol. 2003;57:1471-1475.
16. Araie M, Shirato S, Yamazaki Y, et al. Clinical efficacy of topical nipradilol and timolol on visual field performance in normal-tension glaucoma: A multicenter, randomized, double-masked comparative study. Jpn J Ophthalmol. 2008;52:255-264.
17. Taniai M, Sato E, Mizota A, Adachi-Usami E. Protective action of nipradilol against ischemia-induced retinal damage in rats. Ophthalmic Res. 2002;34:331-337.
18. Mizuno K, Koide T, Saito N, et al. Topical nipradilol: Effects on optic nerve head circulation in humans and periocular distribution in monkeys. Invest Ophthalmol Vis Sci. 2002;43:3243-3250.
19. Kashiwagi K, Lizuka Y, Tsukahara S. Neuroprotective effects of nipradilol on purified cultured retinal ganglion cells. J Glaucoma. 2002;11:231-238.
20. Mizuno K, Koide T, Yoshimura M, Araie M. Neuroprotective effect and intraocular penetration of nipradilol, a beta-blocker with nitric oxide donative action. Invest Ophthalmol Vis Sci. 2001;42:688-694.